Login
ZIOPHARM Oncology NASDAQ: ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
| Name | ZIOPHARM Oncology |
| Ticker | ZIOP |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Price | 2.92 |
| 52W Low/High | 1.90 / 5.29 |
| Market cap | 625 M |
| 1Y Total Return |
-44.59%
Weak |
| 1Y Volatility |
80.04%
High Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
ZIOPHARM Oncology, Inc. is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology
Details
| Ticker | ZIOP |
| Name | ZIOPHARM Oncology |
| ISIN | US98973P1012 |
| CUSIP | 98973P101 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Biopharmaceuticals |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 11/25/20
| Close Price | 2.92 |
| 52W Low/High | 1.90 / 5.29 |
| Market cap | 625 M |
| 1Y Total Return |
-44.59%
Weak |
| 1Y Volatility |
80.04%
High Risk |
| Beta | 1.93 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | - |
| Cash from Op. / Cur. Liabilities | -2.67 |
| Diluted Earnings / Share | -0.36 |
| ROE | - |
| ROIC | -499.7% |
| Price / Revenue | - |
| Price / Book | 4.3 |
| Price / CF | -12.0 |
| Current Ratio | 8.0 |
| Cur.Liabilities / Tot.Liabilities | 0.9 |
| Financial Leverage | 0.01 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
0
|
0
|
2
|
6
|
7
|
4
|
|
| Gross Profit |
-
|
-
|
2
|
6
|
7
|
4
|
|
| R&D |
49
|
36
|
37
|
43
|
157
|
107
|
|
| EBITDA |
-72
|
93
|
-53
|
-52
|
-163
|
-121
|
|
| Operating Income |
-74
|
-55
|
-55
|
-51
|
-164
|
-120
|
|
| Net Income exc. Extra |
-
|
93
|
-
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
213
|
171
|
141
|
141
|
130
|
130
|
|
| EPS exc. Extra |
-0.36
|
0.77
|
-0.52
|
-0.52
|
-1.28
|
-1.04
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
166
|
118
|
67
|
117
|
117
|
173
|
|
| Cash, Eq & Invt ShortTerm |
136
|
89
|
32
|
85
|
95
|
164
|
|
| Total Current Assets |
155
|
116
|
47
|
115
|
116
|
172
|
|
| Total Non-Current Assets |
11
|
2
|
20
|
2
|
1
|
1
|
|
| Intangibles |
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
21
|
12
|
63
|
57
|
60
|
80
|
|
| Total Current Liabilities |
19
|
11
|
60
|
18
|
16
|
30
|
|
| Long Term Debt |
2
|
1
|
3
|
39
|
44
|
50
|
|
| Shareholder equity |
145
|
106
|
-156
|
-80
|
-64
|
94
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-52
|
-41
|
-50
|
-56
|
-69
|
14
|
|
| Depreciation |
1
|
1
|
1
|
0
|
0
|
0
|
|
| Cash from Investing |
-6
|
0
|
-1
|
-1
|
-1
|
0
|
|
| Capex |
6
|
0
|
1
|
1
|
1
|
0
|
|
| Cash from Financing |
105
|
97
|
-2
|
46
|
1
|
104
|
|
| Stock Issued |
105
|
56
|
-2
|
46
|
1
|
104
|
|
| Debt (LT) Issued |
0
|
47
|
0
|
0
|
0
|
0
|
|
| Free Cash Flow |
-72
|
42
|
-12
|
-50
|
-178
|
-103
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Current Ratio |
8.0
|
10.3
|
0.8
|
6.3
|
7.3
|
5.8
|
|
| Financial Leverage D/E |
0.01
|
0.01
|
-
|
-
|
-
|
0.00
|
|
| Return on Capital Avg |
-499.7%
|
-
|
-
|
-512.4%
|
-
|
-
|
|
| Return on Shareholder Equity |
-
|
-367.8%
|
-
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available